[go: up one dir, main page]

ATE225400T1 - Verwendung der leserahmen der adenoviralen e4- region zur verbesserung der genexpression - Google Patents

Verwendung der leserahmen der adenoviralen e4- region zur verbesserung der genexpression

Info

Publication number
ATE225400T1
ATE225400T1 AT99401645T AT99401645T ATE225400T1 AT E225400 T1 ATE225400 T1 AT E225400T1 AT 99401645 T AT99401645 T AT 99401645T AT 99401645 T AT99401645 T AT 99401645T AT E225400 T1 ATE225400 T1 AT E225400T1
Authority
AT
Austria
Prior art keywords
expression
adenoviral
improve
gene expression
orf6
Prior art date
Application number
AT99401645T
Other languages
English (en)
Inventor
Majid Mehtali
Monika Lusky
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Application granted granted Critical
Publication of ATE225400T1 publication Critical patent/ATE225400T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/008Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00Vectors comprising a special translation-regulating system
    • C12N2840/44Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
AT99401645T 1998-07-07 1999-07-01 Verwendung der leserahmen der adenoviralen e4- region zur verbesserung der genexpression ATE225400T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98401722 1998-07-07
EP98402825 1998-11-13

Publications (1)

Publication Number Publication Date
ATE225400T1 true ATE225400T1 (de) 2002-10-15

Family

ID=26151663

Family Applications (2)

Application Number Title Priority Date Filing Date
AT99401645T ATE225400T1 (de) 1998-07-07 1999-07-01 Verwendung der leserahmen der adenoviralen e4- region zur verbesserung der genexpression
AT01124236T ATE258228T1 (de) 1998-07-07 1999-07-01 Verwendung der leserahmen der adenoviralen e4- region zur verbesserung der genexpression

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT01124236T ATE258228T1 (de) 1998-07-07 1999-07-01 Verwendung der leserahmen der adenoviralen e4- region zur verbesserung der genexpression

Country Status (11)

Country Link
US (1) US6475480B1 (de)
EP (2) EP0974668B1 (de)
JP (1) JP2000106875A (de)
AT (2) ATE225400T1 (de)
AU (1) AU756607B2 (de)
CA (1) CA2276791A1 (de)
DE (2) DE69914382T2 (de)
DK (2) DK0974668T3 (de)
ES (2) ES2180258T3 (de)
HK (1) HK1043390A1 (de)
PT (2) PT1199368E (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6225113B1 (en) * 1998-12-04 2001-05-01 Genvec, Inc. Use of trans-activation and cis-activation to modulate the persistence of expression of a transgene in an at least E4-deficient adenovirus
EP1301612A2 (de) * 2000-05-31 2003-04-16 Genvec, Inc. Verfahren und zusammenfassung zur zielrichtung von adenoviralen vektoren
EP1203819A3 (de) 2000-10-06 2002-08-07 Transgene S.A. Entzündungshemmende Vektoren
WO2004018627A2 (en) * 2002-08-22 2004-03-04 Merck & Co., Inc. Methods for propagating adenovirus and virus produced thereby
DE602004031681D1 (de) 2003-07-21 2011-04-14 Transgene Sa Multifunktionelle Cytokine
CA2592699C (en) * 2004-12-31 2023-02-21 Per Sonne Holm Method for reversing multiple resistance in animal cells
US20080166322A1 (en) * 2006-12-08 2008-07-10 Atkinson Richard L Methods for producing an adenovirus type 5 gene transfer vector
US8465732B2 (en) * 2007-01-19 2013-06-18 Cornell Research Foundation, Inc. Endothelial cells expressing adenovirus E4ORF1 and methods of use thereof
SG187785A1 (en) 2010-08-16 2013-03-28 Salk Inst For Biological Studi Anti-cancer adenoviruses
KR101522341B1 (ko) * 2012-10-02 2015-05-21 국립암센터 신규한 조건부-복제 가능 아데노바이러스 및 그의 제조 방법
US9657076B2 (en) 2012-10-23 2017-05-23 Emory University GM-CSF and IL-4 conjugates, compositions, and methods related thereto
WO2014153204A1 (en) 2013-03-14 2014-09-25 Salk Institute For Biological Studies Oncolytic adenovirus compositions
WO2017147269A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
US11826423B2 (en) 2016-11-16 2023-11-28 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
EP3532082A4 (de) 2016-12-12 2020-08-26 Salk Institute for Biological Studies Auf tumoren gerichtete synthetische adenoviren und verwendungen davon
US11203629B2 (en) 2017-04-22 2021-12-21 Immunomic Therapeutics, Inc. LAMP constructs
AU2018263923B9 (en) 2017-05-02 2024-09-19 Immunomic Therapeutics, Inc. LAMP (lysosomal associated membrane protein) constructs comprising cancer antigens
AU2018266705B2 (en) 2017-05-08 2023-05-04 Gritstone Bio, Inc. Alphavirus neoantigen vectors
WO2019222281A1 (en) 2018-05-15 2019-11-21 Immunomic Therapeutics, Inc Improved lamp constructs comprising allergens
AU2020282369A1 (en) 2019-05-30 2022-01-20 Gritstone Bio, Inc. Modified adenoviruses
CA3153850A1 (en) 2019-10-18 2021-04-22 Teri Heiland Improved lamp constructs comprising cancer antigens
CN110714027A (zh) * 2019-10-28 2020-01-21 嘉铭(固安)生物科技有限公司 一种表达质粒、用于包装二代腺病毒的细胞株及其应用
CN110656090B (zh) * 2019-10-28 2023-06-30 嘉兴安宇生物科技有限公司 一种表达质粒、用于包装容量增加的二代腺病毒的细胞株及其应用
WO2022007800A1 (zh) * 2020-07-06 2022-01-13 嘉兴安宇生物科技有限公司 一种非洲猪瘟的重组腺病毒疫苗及其构建方法
KR20220106072A (ko) 2021-01-21 2022-07-28 주식회사 셀리드 복제가능 아데노바이러스를 포함하지 않는 신규 아데노바이러스 벡터 및 이의 용도
CN119233982A (zh) 2022-04-10 2024-12-31 免疫治疗有限公司 包含免疫应答增强基因的双顺反子lamp构建体及其使用方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670488A (en) * 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
EP0905253A3 (de) * 1992-12-03 2000-11-02 Genzyme Corporation Von allen E4-ORF ausgenommen ORF6 deletierte Adenovirus-Vector
FR2726285B1 (fr) * 1994-10-28 1996-11-29 Centre Nat Rech Scient Adenovirus depourvus de particules contaminantes viables, preparation et utilisation
US5756283A (en) * 1995-06-05 1998-05-26 The Trustees Of The University Of Pennsylvania Method for improved production of recombinant adeno-associated viruses for gene therapy
WO1998021350A1 (en) * 1996-11-13 1998-05-22 Board Of Regents, The University Of Texas System Diminishing viral gene expression by promoter replacement
US6100086A (en) * 1997-04-14 2000-08-08 Genzyme Corporation Transgene expression systems
US5981275A (en) * 1997-04-14 1999-11-09 Genzyme Corporation Transgene expression system for increased persistence

Also Published As

Publication number Publication date
PT1199368E (pt) 2004-04-30
AU756607B2 (en) 2003-01-16
ES2180258T3 (es) 2003-02-01
DK0974668T3 (da) 2002-11-11
DE69914382T2 (de) 2004-11-04
US6475480B1 (en) 2002-11-05
EP0974668A1 (de) 2000-01-26
DK1199368T3 (da) 2004-04-13
ES2210081T3 (es) 2004-07-01
JP2000106875A (ja) 2000-04-18
EP0974668B1 (de) 2002-10-02
DE69914382D1 (de) 2004-02-26
PT974668E (pt) 2003-01-31
ATE258228T1 (de) 2004-02-15
DE69903229T2 (de) 2003-06-26
DE69903229D1 (de) 2002-11-07
EP1199368A2 (de) 2002-04-24
EP1199368A3 (de) 2002-07-17
HK1043390A1 (zh) 2002-09-13
AU3800999A (en) 2000-06-08
CA2276791A1 (en) 2000-01-07
EP1199368B1 (de) 2004-01-21

Similar Documents

Publication Publication Date Title
ATE225400T1 (de) Verwendung der leserahmen der adenoviralen e4- region zur verbesserung der genexpression
PL397823A1 (pl) Sposób identyfikacji serotypu sekwencji wirusa stowarzyszonego z adenowirusem (AAV), zestaw diagnostyczny, sposób izolacji nowych wirusów, nowy serotyp wirusa, wyizolowane wirusy, białka obejmujące fragment białka kapsydu AAV, sztuczne białka, zrekombinowany wirus, cząsteczki, sposób wytwarzania zrekombinowanych wirusów, komórki gospodarza, kompozycje, sposób dostarczania transgenu, wyizolowany AAV, rekombinowana komórka, sposób wytwarzania rekombinowanego wirusa, zastosowanie wirusa
WO2005001103A3 (en) Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
WO2001083692A3 (en) Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids
SI1496944T1 (sl) Izboljšani sistemi ekspresije RAAV za genetsko modifikacijo specifičnih kapsidnih proteinov
ATE286138T1 (de) Zusammensetzungen und verfahren zur helfer-freien herstellung von rekombinante adeno-assoziierten viren
CA2305623A1 (fr) Circovirus porcins, vaccins et reactifs de diagnostic
DK1127150T3 (da) Nucleinsyresekvenser fra det adeno-associerede virus af serotype 1 samt vektorer og værtsceller, der indeholder disse
AUPN477695A0 (en) Gene therapy
ES2337768T3 (es) Metodo para purificar adenovirus.
CA2323862A1 (en) Maturation of somatic embryos
WO2006116267A3 (en) Cell-specific molecule and method for importing dna into osteoblast nuclei
WO1998055639A3 (fr) Vecteurs adenoviraux recombinants comprenant une sequence d'epissage
CA2167578A1 (en) Chicken anemia virus mutants and vaccines and uses based on the viral proteins vp1, vp2 and vp3 or sequences of that virus coding therefor
ATE377088T1 (de) Promotoren zur expression in modifiziertem vaccinia virus ankara
EP0752888A4 (de) NUKLEOTID- AMINOSÄURESEQUENZEN DER HERPEVIREN gB,gC UND gD AUS HUND UND IHRE VERWENDUNGEN
DE69929530D1 (de) Attenuierte pferdeherpesvirus
WO2005010149A3 (en) Subgroup b adenoviral vectors for treating disease
MXPA02012593A (es) Particulas de tipo virus del virus de la diarrea viral bovina.
DE69031803D1 (de) Verfahren und nukleinsäuresequenzen zur expression des zellulose-synthase-operons
WO2006086357A3 (en) Adenovirus serotype 36 vectors, nucleic acid and viruses produced thereby
EP1845163A3 (de) Adeno-assoziierte Virus-Serotyp-I-Nukleinsäuresequenzen und diese enthaltende Vektoren und Wirtszellen
EP4407025A3 (de) Adenovirus mit modifiziertem adenovirus-hexon-protein
WO2003031633A3 (de) Adenovirales vektorsystem
Agrawal et al. 800. Generation of Recombinant Skin In Vitro by Adeno-Associated Virus Type 2 Vector Transduction

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0974668

Country of ref document: EP

REN Ceased due to non-payment of the annual fee